● neutral
Impact
PhaseNot stated
Time to marketUnknown — DISC-0998 was not identified as a real development program in any accessible database.
DISC-0998 Updated Oct 24
What to watch
DISC-0998 does not appear in any publicly-tracked database or filing, it is likely an erroneous or obsolete code. Investors should focus on Disc Medicine's confirmed lead asset bitopertin (DISC-1459), which posted positive Phase 3 APOLLO topline data in October 2026 and is the primary value driver with an FDA decision expected mid-2027.
Bull case
- If DISC-0998 is a real early/preclinical asset not yet public, the company's strong analyst consensus (18 Buy/Strong Buy vs 1 Hold, mean target $123.25 implying ~65% upside) and institutional backing (top holders FMR, BlackRock, RA Capital) provide a robust development platform.
- Disc Medicine completed a $450M upsized offering in October 2026, extending cash runway into 2030, ample resources to advance any pipeline program.
Bear case
- No evidence DISC-0998 exists as a real program in any public or ingested database, it may be a typographical error, an abandoned compound, or an internal code that never reached disclosure.
- Disc Medicine's confirmed pipeline (bitopertin, selcodebart, DISC-3405, DISC-0974) bears no relation to 'DISC-0998', raising the risk that the filing hint is simply wrong.